MeSH tree: C04.557.386.480.150.585
An international team of doctors led by Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at Mount Sinai, has made a major breakthrough in treating a common and challenging form ...
Jan 23, 2025
0
19
A simple dietary supplement may provide a new approach to boost CAR T cell function, according to a study by researchers in the Perelman School of Medicine at the University of Pennsylvania and Penn Medicine's Abramson Cancer ...
Dec 7, 2024
0
143
In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely rare after two weeks, supporting a shorter, more flexible toxicity ...
Jul 24, 2024
0
35
A study led by researchers at Brighton and Sussex Medical School (BSMS) has unveiled an approach to predicting the effectiveness of treatments for patients with diffuse large B-cell lymphoma (DLBCL), a common form of blood ...
Jul 15, 2024
0
35
CAR-T cell therapy, which targets a specific protein on the surface of cancer cells, causes tumors to shrink or disappear in about half of patients with large B-cell lymphoma who haven't experienced improvement with chemotherapy ...
Jul 10, 2024
0
36
Glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) is superior to rituximab (R)-GemOx for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), according to a study presented at the annual hybrid congress ...
Jun 26, 2024
0
36
Researchers at the National Institutes of Health (NIH) have developed a non-chemotherapy treatment regimen that is achieving full remissions for some people with aggressive B-cell lymphoma that has come back or is no longer ...
Jun 19, 2024
0
66
Researchers from the University of Helsinki and HUS investigated the effects of recurring mutations in the KLHL6 gene in diffuse large B-cell lymphoma, the most common cancer of the lymphatic system.
Jun 18, 2024
0
29
A team of cancer researchers, led by the University of Houston, has discovered a new subset of T cells that may improve the outcome for patients treated with T-cell therapies.
May 28, 2024
0
46
Researchers from the Cancer Science Institute of Singapore (CSI) at the National University of Singapore (NUS), have achieved breakthroughs in understanding relapse after chemotherapy for a type of cancer known as diffuse ...
May 13, 2024
0
43
